181
Participants
Start Date
April 20, 2017
Primary Completion Date
May 7, 2020
Study Completion Date
September 5, 2023
Atezolizumab (MPDL3280A), an engineered anti-PD-L1 antibody
Atezolizumab was given as 1200 milligrams (mg) via intravenous (IV) infusion on Day 1 of each 21-day cycle.
New York University Medical Center, New York
Memorial Sloan Kettering - Basking Ridge, New York
Memorial Sloan Kettering Cancer Center, New York
Memorial Sloan Kettering Cancer Center at Westchester, Harrison
Memorial Sloan Kettering Nassau, Uniondale
Memorial Sloan Kettering Cancer Center - Commack, Commack
Emory University; Winship Cancer Institute, Atlanta
Moffitt Cancer Center, Tampa
The Ohio State University Comprehensive Cancer Center, Columbus
Karmanos Cancer Inst; Hematology/Oncology, Detroit
Washington University; Wash Uni. Sch. Of Med, St Louis
University Of Colorado, Aurora
UCLA Cancer Center, Santa Monica
City of Hope Comprehensive Cancer Center, Duarte
Yale Cancer Center, New Haven
Dana Farber Cancer Institute; Brigham and Womens Hospital, Boston
Mass General/North Shore Cancer, Danvers
Dartmouth Hitchcock Medical Center, Lebanon
Memorial Sloan Kettering - Monmouth, Middletown
Lead Sponsor
Genentech, Inc.
INDUSTRY